| scholarly article | Q13442814 |
| P50 | author | Caterina Gagliano | Q58806449 |
| Filippo Drago | Q18355267 | ||
| P2093 | author name string | Gaetano Bertino | |
| Giulia Malaguarnera | |||
| Michele Malaguarnera | |||
| Marco Vacante | |||
| Massimo Motta | |||
| Filippo Caraci | |||
| Giuseppe Chisari | |||
| Giuseppe Nunnari | |||
| Carmela Greco | |||
| P2860 | cites work | Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. | Q43818669 |
| Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis | Q43903159 | ||
| Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin | Q44510957 | ||
| Silibinin protects mice from T cell-dependent liver injury | Q44555689 | ||
| Silibinin efficacy against human hepatocellular carcinoma | Q46831116 | ||
| Neuroprotective effect of silibinin in diabetic mice. | Q48862839 | ||
| Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. | Q50537785 | ||
| [Do the interferons have an antifibrotic action? The hepatologist's point of view]. | Q50583785 | ||
| Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. | Q50584678 | ||
| Antioxidant activity of silybin in vivo during long-term iron overload in rats | Q71584393 | ||
| A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis | Q72568821 | ||
| World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects | Q73135842 | ||
| Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1 | Q74603172 | ||
| Regulation of stellate cell proliferation by lipopolysaccharide: role of endogenous nitric oxide | Q77475931 | ||
| Identification of hepatoprotective flavonolignans from silymarin | Q24600492 | ||
| Second-generation line probe assay for hepatitis C virus genotyping | Q27485722 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group | Q29614898 | ||
| Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis | Q29619627 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin | Q33398403 | ||
| Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial | Q33647262 | ||
| Hepatic fibrosis | Q33904174 | ||
| Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials | Q33965076 | ||
| Roles of TGF-beta in hepatic fibrosis | Q34565570 | ||
| Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin | Q34626058 | ||
| Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients. | Q35507354 | ||
| Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. | Q35610868 | ||
| Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). | Q35977431 | ||
| Silymarin use and liver disease progression in the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis trial | Q36374902 | ||
| Reversibility of liver fibrosis. | Q37653696 | ||
| Management of varices and variceal hemorrhage in cirrhosis | Q37702063 | ||
| The physiopathology of lipoprotein (a). | Q37762030 | ||
| Review article: the reversibility of cirrhosis | Q38042443 | ||
| Epidemiology and natural history of HCV infection. | Q38118578 | ||
| Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results | Q39509094 | ||
| Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 | ||
| Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. | Q42981378 | ||
| Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. | Q42998101 | ||
| A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. | Q43035164 | ||
| Diagnosing and treating hepatitis C virus infection | Q43038727 | ||
| A proposed system for the nomenclature of hepatitis C viral genotypes | Q43049109 | ||
| Differences in epidemiology, liver disease and treatment response among HCV genotypes | Q43603868 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribavirin | Q421862 |
| pegylated interferon | Q7160835 | ||
| P304 | page(s) | 2510-2518 | |
| P577 | publication date | 2015-11-15 | |
| P1433 | published in | American Journal of Translational Research | Q4744272 |
| P1476 | title | Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin | |
| P478 | volume | 7 |
| Q64249929 | Antiviral Activities of Silymarin and Derivatives |
| Q26750646 | Hepatocellular carcinoma and the risk of occupational exposure |
| Q49568112 | PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). |
| Q37227987 | Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro |
| Q55465315 | Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. |
| Q40078355 | Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. |
| Q36192046 | Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability. |
| Q47135887 | Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
| Q64054773 | Vitamin D Serum Levels in Patients with Statin-Induced Musculoskeletal Pain |
Search more.